Pancreatic Cancer Clinical Trials

Showing 1-20 of 1,019 trials

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

NCT04137536

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

Pancreatic CancerAdvanced Pancreatic CancerPancreatic Adenocarcinoma+1 more

Memorial Sloan Kettering Cancer Center7 participantsStarted Oct 2019

New York, New York, United States • Charlottesville, Virginia, United States

RECRUITINGPhase 1

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Colorectal CancerPancreatic CancerNon-Small Cell Lung Cancer+1 more

PAQ Therapeutics, Inc.195 participantsStarted Nov 2025

Boston, Massachusetts, United States • San Antonio, Texas, United States • San Antonio, Texas, United States +2 more locations

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Related Searches

Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

DESTINY-PANTUMOUR04

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Familial Investigations of Childhood Cancer Predisposition

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Intraoperative Endoscopic Ultrasound for Pancreatic Cancer

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer